HomeWorldHow Dominari went from failed biotech to Trump Tower dealmaker for the first family

How Dominari went from failed biotech to Trump Tower dealmaker for the first family

A little-known firm pivoted from drug research to finance and became central to Trump family ventures in crypto and manufacturing.

August 20, 2025 / 13:05 IST
Story continues below Advertisement
How Dominari went from failed biotech to Trump Tower dealmaker for the first family (Image: WSJ)
How Dominari went from failed biotech to Trump Tower dealmaker for the first family (Image: WSJ)

Dominari Holdings began life decades ago as a biotech company once known as Spherix and later AIkido Pharma. After years of heavy losses, it shifted strategy in 2021 under CEO Anthony Hayes. Seeking new ground, Hayes brought in veteran banker Kyle Wool, who helped the firm pivot from speculative drug research into finance. Their move into Trump Tower marked the turning point that would transform their fortunes, the Wall Street Journal reported.

Betting on Trump at a low point

Story continues below Advertisement

At the time, Donald Trump faced legal scrutiny and political isolation following the January 6 riot. Wall Street was keeping its distance, but Hayes and Wool saw an opportunity. By leasing space in Trump Tower, they positioned themselves near Trump’s sons, Eric and Don Jr. Golf outings and personal connections soon developed into business ties, placing Dominari inside the family’s growing circle of advisers.

Building credibility through access